STOCK TITAN
  1. Home
  2. Sec-filings
  3. PMVP
  4. [Form 4] PMV Pharmaceuticals, Inc. Insider Trading Activity

PMVP insider filing shows 1M-share sale, ongoing indirect holdings

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PMV Pharmaceuticals (PMVP) — Form 4 insider transaction: An affiliated holder reported a sale of 1,000,000 shares of Common Stock on 10/23/2025 at a price of $1.52 per share. Following the transaction, 4,975,291 shares were reported as beneficially owned indirectly.

According to the footnotes, the shares are held by OrbiMed Private Investments V, LP, with OrbiMed Capital GP V LLC as general partner and OrbiMed Advisors LLC as managing member. The filing notes that the reporting persons may be deemed to share voting and investment power through these relationships and include customary disclaimers of beneficial ownership beyond pecuniary interest. The reporting relationship is indicated as Director and 10% Owner.

Positive

  • None.

Negative

  • None.

Insights

Neutral Form 4: fund-affiliated sale with ongoing indirect holdings.

This filing reports a sale of 1,000,000 PMVP common shares at $1.52 on 10/23/2025. After the sale, the filer reports 4,975,291 shares beneficially owned indirectly. The disclosure centers on a change in indirect holdings by an affiliated investment entity.

Footnotes attribute ownership to OrbiMed Private Investments V, LP, with OrbiMed Capital GP V LLC and OrbiMed Advisors LLC in control roles. Standard disclaimers limit beneficial ownership to pecuniary interest and avoid admissions under Section 16.

As a routine Section 16 update, the market impact depends on context not provided here. Actual effects, if any, would hinge on broader trading activity and subsequent disclosures.

Insider ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC
Role 10% Owner | 10% Owner
Sold 1,000,000 shs ($1.52M)
Type Security Shares Price Value
Sale Common Stock 1,000,000 $1.52 $1.52M
Holdings After Transaction: Common Stock — 4,975,291 shares (Indirect, See Footnotes)
Footnotes (1)
  1. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC
(Last) (First) (Middle)
601 LEXINGTON AVENUE
54TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/23/2025 S 1,000,000 D $1.52 4,975,291 I See Footnotes(1)(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
ORBIMED ADVISORS LLC
(Last) (First) (Middle)
601 LEXINGTON AVENUE
54TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
OrbiMed Capital GP V LLC
(Last) (First) (Middle)
601 LEXINGTON AVENUE
54TH FLOOR
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.
2. This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC 10/27/2025
/s/ Carl L. Gordon, Member of the Managing Member of OrbiMed Capital GP V LLC 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did PMVP’s Form 4 report on 10/23/2025?

A sale of 1,000,000 shares of PMV Pharmaceuticals common stock at $1.52 per share.

How many PMVP shares remain beneficially owned after the transaction?

The filing reports 4,975,291 shares beneficially owned indirectly following the sale.

Who are the reporting persons associated with the PMVP Form 4?

The filing identifies OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, tied to OrbiMed Private Investments V, LP.

What relationships to PMVP are indicated in the filing?

The reporting relationship is marked as Director and 10% Owner.

How was ownership of the PMVP shares held?

Indirectly through OrbiMed Private Investments V, LP, with related entities in control roles, as described in the footnotes.

Does the Form 4 include beneficial ownership disclaimers?

Yes. It states ownership is disclaimed beyond pecuniary interest and is not an admission under Section 16.